KRAS and malignant colon neoplasm: Together, these findings imply the oncogenic property of ACSL4 in colon cancers, with 30–40% of the tumors carrying a KRAS mutation, in which KRAS G12V mutation is one of the major pathologic features of SW480 as a colorectal cancer cell line.